Entinostat, a histone deacetylase (HDAC) inhibitor, has been shown to enhance antigen presentation and modulate immune checkpoint expression, thereby promoting anti-tumor immunity—a mechanism consistent with the immune-related pathway enrichment in the high-risk group (41–43). Here, HDAC9 is linked to neoplasm.